In conclusion, results of this study suggest a positive effect of IL-1 inhibition in patients with RA and T2D, reaching the therapeutic targets of both diseases and improving the main outcome of enrolled participants. This evidence concerns the gene IL1B and type 2 diabetes mellitus.